Q1 FY27 snapshot
Announcement Date31-Jul-26
Revenue (Top Line)₹270 Cr
Net Profit (Bottom Line)₹59 Cr
Earnings Per Share (EPS)₹5.59
Expenses₹212 Cr
Net profit margin (calculated)21.9%
Concord Biotech Ltd. (CONCORDBIO) Quarterly Results: Q1 FY27
Quick answer: Concord Biotech Ltd. (NSE: CONCORDBIO) reported Q1 FY27 revenue of ₹270 Cr and net profit of ₹59 Cr, with earnings per share (EPS) of ₹5.59, announced on 31-Jul-26.
That works out to a net profit margin of about 21.9% for the quarter.
Note: figures are pulled automatically from company filings and may lag or contain gaps. Verify on NSE or BSE. Not investment advice.
How to read Concord Biotech Ltd.'s Q1 FY27 results
Revenue of ₹270 Cr is what Concord Biotech Ltd. earned before costs. Net profit of ₹59 Cr is what remained for shareholders after expenses, interest and tax. Dividing one by the other gives a net margin of about 21.9%, a quick gauge of how much of each rupee of sales is kept as profit.
New to results? Read our guide on how to read quarterly results, see the full results list or the dividend calendar.
FAQs
Concord Biotech Ltd. results FAQs
What were Concord Biotech Ltd.'s Q1 FY27 results?
Concord Biotech Ltd. (NSE: CONCORDBIO) reported Q1 FY27 revenue of ₹270 Cr and net profit of ₹59 Cr, with earnings per share (EPS) of ₹5.59, announced on 31-Jul-26.
What is Concord Biotech Ltd.'s EPS for Q1 FY27?
Concord Biotech Ltd.'s earnings per share for Q1 FY27 was ₹5.59. EPS is net profit divided by the number of outstanding shares.
When did Concord Biotech Ltd. announce its Q1 FY27 results?
Concord Biotech Ltd. announced its Q1 FY27 results on 31-Jul-26.
What is Concord Biotech Ltd.'s net profit margin?
On the reported figures, Concord Biotech Ltd.'s Q1 FY27 net profit margin is about 21.9% (net profit ÷ revenue).